C225

Phase 2Small molecule

FFudan University

C225 is one of 18 small molecule programs targeting Hypofractionated Radiotherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypofractionated RadiotherapyRecruiting

Hypofractionated RadiotherapyPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Hypofractionated Radiotherapy

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 2

3 2

Camptosar

Pfizer

Phase 2

2 3

Eloxatin

Teva

Phase 2

2 4

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Phase 3

2 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 6

Erbitux

IImclone

Phase 2

2 7

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 8

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

1 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 10

Folinic Acid

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Hypofractionated Radiotherapy

NCT07183865

Clinical

Trials by Indication[1]

Hypofractionated Radiotherapy1 trial

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Recruiting·FFudan University·Phase 2·NCT07183865·44 enrolled

Nasopharyngeal Carcinoma1 trial

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy

Completed·SSun Yat-sen University·Phase 2·NCT00700440·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for C225. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — C225 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for C225. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

C225

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Hypofractionated Radiotherapy1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News